OOIR: Observatory of International Research

Papers

(The TQCC of Molecular Neurodegeneration is 25. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-01-01 to 2025-01-01.)

Article	Citations
LRP1: a novel receptor for the transmission of pathological α-Synuclein	258
Valosin containing protein (VCP): initiator, modifier, and potential drug target for neurodegenerative diseases	227
In Memoriam of John T. Trojanowski, MD, PhD 1946-2022	153
Regulation of cortical hyperexcitability in amyotrophic lateral sclerosis: focusing on glial mechanisms	148
The informed road map to prevention of Alzheimer Disease: A call to arms	148
Mitochondrial CISD1/Cisd accumulation blocks mitophagy and genetic or pharmacological inhibition rescues neurodegenerative phenotypes in Pink1/parkin models	142
Tau interactome and RNA binding proteins in neurodegenerative diseases	132
Fluid biomarkers for amyotrophic lateral sclerosis: a review	130
Nuclear import receptors are recruited by FG-nucleoporins to rescue hallmarks of TDP-43 proteinopathy	126
The TGFβ/Notch axis facilitates Müller cell-to-epithelial transition to ultimately form a chronic glial scar	122
AMPK hyperactivation promotes dendrite retraction, synaptic loss, and neuronal dysfunction in glaucoma	121
A proteomic network approach resolves stage-specific molecular phenotypes in chronic traumatic encephalopathy	120
A microglial activity state biomarker panel differentiates FTD-granulin and Alzheimer’s disease patients from controls	119
Pharmacological rescue of cognitive function in a mouse model of chemobrain	115
Regulation of the hippocampal translatome by Apoer2-ICD release	114
Glial interference: impact of type I interferon in neurodegenerative diseases	113
Modulating innate immune activation states impacts the efficacy of specific Aβ immunotherapy	112
AIF3 splicing switch triggers neurodegeneration	108
Melatonin: a ferroptosis inhibitor with potential therapeutic efficacy for the post-COVID-19 trajectory of accelerated brain aging and neurodegeneration	104
An adapted protocol to derive microglia from stem cells and its application in the study of CSF1R-related disorders	101
Astrocytes of the optic nerve exhibit a region-specific and temporally distinct response to elevated intraocular pressure	100
News & views: anti-amyloid antibodies and novel emerging approaches to Alzheimer’s disease in 2023	99
Microglial CD2AP deficiency exerts protection in an Alzheimer’s disease model of amyloidosis	95
Mis-localization of endogenous TDP-43 leads to ALS-like early-stage metabolic dysfunction and progressive motor deficits	90
A Trem2R47H mouse model without cryptic splicing drives age- and disease-dependent tissue damage and synaptic loss in response to plaques	82

A partial Drp1 knockout improves autophagy flux independent of mitochondrial function	72
Cerebrospinal fluid lipoproteins inhibit α-synuclein aggregation by interacting with oligomeric species in seed amplification assays	70
Genome-wide histone acetylation analysis reveals altered transcriptional regulation in the Parkinson’s disease brain	70
Unraveling the complex role of MAPT-containing H1 and H2 haplotypes in neurodegenerative diseases	69
Alzheimer’s disease: targeting the peripheral circulation	69
Amyloid-β specific regulatory T cells attenuate Alzheimer’s disease pathobiology in APP/PS1 mice	67
Retinal ganglion cell repopulation for vision restoration in optic neuropathy: a roadmap from the RReSTORe Consortium	67
CSF proteins of inflammation, proteolysis and lipid transport define preclinical AD and progression to AD dementia in cognitively unimpaired individuals	62
Microglial TYROBP/DAP12 in Alzheimer’s disease: Transduction of physiological and pathological signals across TREM2	61
Optimizing detection of Alzheimer’s disease in mild cognitive impairment: a 4-year biomarker study of mild behavioral impairment in ADNI and MEMENTO	61
Brain mechanisms underlying neuropsychiatric symptoms in Alzheimer’s disease: a systematic review of symptom-general and –specific lesion patterns	60
Specific detection of tau seeding activity in Alzheimer’s disease using rationally designed biosensor cells	59
TREM2 dependent and independent functions of microglia in Alzheimer’s disease	58
Opposing effects of apoE2 and apoE4 on microglial activation and lipid metabolism in response to demyelination	57
Common features of neurodegenerative disease: exploring the brain-eye connection and beyond (Part 1): the 2021 pre-symposium of the 15th international conference on Alzheimer’s and Parkinson’s disease	57
APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer’s disease pathology and brain diseases	56
Leveraging the glymphatic and meningeal lymphatic systems as therapeutic strategies in Alzheimer’s disease: an updated overview of nonpharmacological therapies	55
Guidelines for bioinformatics of single-cell sequencing data analysis in Alzheimer’s disease: review, recommendation, implementation and application	55
Extracellular protein components of amyloid plaques and their roles in Alzheimer’s disease pathology	54
Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications	53
Pathophysiology and probable etiology of cerebral small vessel disease in vascular dementia and Alzheimer’s disease	52
Challenge accepted: uncovering the role of rare genetic variants in Alzheimer’s disease	50
TDP-43 pathology is associated with increased tau burdens and seeding	50
High dose expression of heme oxigenase-1 induces retinal degeneration through ER stress-related DDIT3	50
Aging-associated sensory decline and Alzheimer’s disease	48
Correction to: Plaque associated microglia hyper-secrete extracellular vesicles and accelerate tau propagation in a humanized APP mouse model	48
A novel AAV Vector for gene therapy of RPE-related retinal degenerative diseases via intravitreal delivery	47
TREM2 and microglia exosomes: a potential highway for pathological tau	45
Whole-genome sequencing analysis reveals new susceptibility loci and structural variants associated with progressive supranuclear palsy	44
Targeted degradation of ⍺-synuclein aggregates in Parkinson’s disease using the AUTOTAC technology	43
Correction: Multi-modal proteomic characterization of lysosomal function and proteostasis in progranulin-deficient neurons	43
Drug development targeting degeneration of the basal forebrain cholinergic system: its time has come	42
Current views on meningeal lymphatics and immunity in aging and Alzheimer’s disease	41
The gut microbiome regulates astrocyte reaction to Aβ amyloidosis through microglial dependent and independent mechanisms	40
Novel App knock-in mouse model shows key features of amyloid pathology and reveals profound metabolic dysregulation of microglia	39
ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies	39
One immune cell to bind them all: platelet contribution to neurodegenerative disease	39
Untargeted serum metabolomics reveals novel metabolite associations and disruptions in amino acid and lipid metabolism in Parkinson’s disease	39
Clarifying the association of CSF Aβ, tau, BACE1, and neurogranin with AT(N) stages in Alzheimer disease	37
Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration	36
Circadian clocks, cognition, and Alzheimer’s disease: synaptic mechanisms, signaling effectors, and chronotherapeutics	36
Astrocytic APOE4 removal confers cerebrovascular protection despite increased cerebral amyloid angiopathy	36
Clusterin secreted from astrocyte promotes excitatory synaptic transmission and ameliorates Alzheimer’s disease neuropathology	36
Impaired antioxidant KEAP1-NRF2 system in amyotrophic lateral sclerosis: NRF2 activation as a potential therapeutic strategy	35
“Don’t Phos Over Tau”: recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer’s disease and other tauopathies	35
CX3CR1 deficiency aggravates amyloid driven neuronal pathology and cognitive decline in Alzheimer’s disease	35
Correction: Alzheimer risk gene product Pyk2 suppresses tau phosphorylation and phenotypic effects of tauopathy	34
Correction: Predominant expression of Alzheimer’s disease-associated BIN1 in mature oligodendrocytes and localization to white matter tracts	34
Border-associated macrophages promote cerebral amyloid angiopathy and cognitive impairment through vascular oxidative stress	34
Brain clearance of protein aggregates: a close-up on astrocytes	33

Parkinson mice show functional and molecular changes in the gut long before motoric disease onset	33
In memoriam of Huaxi Xu, PhD, 1964–2022	33
Anti-acetylated-tau immunotherapy is neuroprotective in tauopathy and brain injury	32
VCP suppresses proteopathic seeding in neurons	32
Neuronal and glial vulnerability of the suprachiasmatic nucleus in tauopathies: evidence from human studies and animal models	32
Cellular stress signaling and the unfolded protein response in retinal degeneration: mechanisms and therapeutic implications	30
TREM2/PLCγ2 signalling in immune cells: function, structural insight, and potential therapeutic modulation	30
Transcriptome deregulation of peripheral monocytes and whole blood in GBA-related Parkinson’s disease	29
The gut microbiome in Alzheimer’s disease: what we know and what remains to be explored	29
Edaravone activates the GDNF/RET neurotrophic signaling pathway and protects mRNA-induced motor neurons from iPS cells	29
The role of ATP-binding cassette subfamily A in the etiology of Alzheimer’s disease	29
A genome-wide search for pleiotropy in more than 100,000 harmonized longitudinal cognitive domain scores	28
Sex specific molecular networks and key drivers of Alzheimer’s disease	27
Comparing anti-tau antibodies under clinical trials and their epitopes on tau pathologies	26
Collagen in the central nervous system: contributions to neurodegeneration and promise as a therapeutic target	25
α-Synuclein serine129 phosphorylation – the physiology of pathology	25
Human iPSC-derived astrocytes transplanted into the mouse brain undergo morphological changes in response to amyloid-β plaques	25
Knock-in models related to Alzheimer’s disease: synaptic transmission, plaques and the role of microglia	25